mCRPC Treatment COE

The Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade - Wassim Abida

Details
Wassim Abida joins Charles Ryan in a discussion on a JAMA Oncology published paper on the Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. Wassim details the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti–PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. The...

Introducing TIN 117m for Convention Electron Therapy of mCRPC - Suresh Srivastava

Details
Suresh C. Srivastava presents the unique opportunities and future for nuclear medicine, including theragnostic radiopharmaceuticals for molecular imaging plus therapy and getting closer to personalized medicine, selection criteria, production, and the nuclear, physical, and chemical properties of certain dual-purpose radionuclides, including those that are currently being used, or studied and eval...

Current State of Liquid Biopsies in Prostate Cancer - Gert Attard

Details
(Length of Interview: 13 min) Charles Ryan and Gert Attard discuss what is currently being done with regards to serum analysis, plasma analysis, liquid biopsies, circulating tumor cells, in the field of prostate cancer. Biographies: Professor Gerhardt Attard MD Ph.D. FRCP Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He...

Prospective Study of Low-Dose Abiraterone with Food Versus Standard Dose Abiraterone in mCRPC - Russell Szmulewitz

Details
(Length of Discussion: 21 min) Russell Szmulewitz talks with Alicia Morgans about a trial that evaluated abiraterone with food and how that might affect relative patient outcomes, such as PSA. This study sought to test the hypothesis that low-dose Abiraterone acetate (AA) (LOW; 250 mg with a low-fat meal) would have comparable activity to standard dosed AA (STD; 1,000 mg fasting) in patients with...

Exercise in Men with Metastatic Castrate-Resistant Prostate Cancer, the INTERVAL Study - Interview with Fred Saad

Details
(Length of Conversation: 9 min) Fred Saad and Charles Ryan discuss the Movember Foundation sponsored, INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer Study (INTERVAL). This is a randomized phase 3 study of exercise in men with metastatic castrate-resistant prostate cancer (mCRPC). The objective of the study is to determine if high intensity aerobic and re...

The Virility Paradox, A Book Review with Charles Ryan

Details
(Length of Discussion: 28 min) J. Kellogg Parsons, MD interviews Charles Ryan, MD on the release of his first book The Virility Paradox, The Vast Influence of Testosterone on our Bodies, Minds, and the World Around Us. Charles shares the inspiration that drove him to write The Virility Paradox, his take on the influence testosterone has played on evolution, its impact on the way we interact with o...

Practice Changing Events in Prostate Cancer- Charles Ryan

Details
Practice Changing Events in Prostate Cancer, a Conversation with Alicia Morgans and Charles Ryan Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Discussion: 14 min) Alicia Morgans, MD sits down with Charles Ryan, MD to discuss some of the practice changing events in prostate cancer and advanced prostate cancer in 2017. Some of the highlights they cover are the LATITUDE an...

Impacts of Latitude and Stampede: Urologist and Urologic Oncologist's Perspective

Details
(Length of lecture ~ 36 minutes) Alicia Morgans hosts a discussion with David Penson, Charles Ryan and Neal Shore regarding impacts of LATITUDE and STAMPEDE data from a urologist and urologic oncologists perspective, taking in to account the recently updated data from the CHAARTED trial. Specifically, discussed was treating patients that have high-volume, aggressive metastatic prostate cancer that...

Clinical Conversation: CHAARTED, LATITUDE and STAMPEDE

Details
(Length of discussion ~ 27 minutes) Charles Ryan hosts a discussion with Alicia Morgans and Christopher Sweeney regarding data from the LATITUDE, STAMPEDE and CHAARTED trials, and the survivor endpoints for patients receiving initial androgen deprivation therapy (ADT) for metastatic prostate cancer. Specifically, discussed is the interface of these three very important studies and the many treatme...

'Life After the Diagnosis, Expert Advice on Living Well with Serious Illness for Patient and Caregivers' a conversation with Steven Pantilat & Charles Ryan.

Details
(Length of conversation - 39 minutes) Dr. Steve Pantilat talks to UroToday and Charles Ryan, MD. about his new book, 'Life After the Diagnosis, Expert Advice on Living Well With Serious Illness for Patients and Caregivers.' He and Dr. Ryan talk about the questions that patients have and how clinicians can approach the answers that provide the patients the information that they truly need in a way...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe